** Shares of drugmaker Emergent BioSolutions EBS.N fall 3% to $5.60, hit nine-month low
** India's Syngene International SYNN.NS says it has acquired its first biologics facility in the U.S. from Emergent Manufacturing Operations Baltimore, a unit of EBS, for $36.5 million
** The deal is expected to close in March, 2025
** Co says the facility is expected to be operational for client projects from the H2 2025
** Up to last close, EBS has risen more than double in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.